YK Bioventures
Venture capitalActively deployingBurlingame · 2 people tracked
Also known as YK BIOVENTURES CAPITAL PARTNERS LLC
Find your way into YK Bioventures
549 people in our graph share verified history with the YK Bioventures team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
YK Bioventures is a venture fund manager based in Burlingame. SEC filings show 2 venture funds on record, most recently YK Bioventures Opportunities Fund III, L.P. ($250M offering) filed July 2026.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 2 people
from public directoriesWhat they invest in
from 9 of 10 portfolio companiesBiotech ×7Healthtech ×5Deep Tech ×2AI & Machine Learning ×1Consumer ×1Cybersecurity ×1Digital Health ×1Direct to Consumer ×1
HQs:United States×6Colombia×1Germany×1
Investments · 10 tracked
founders shown can be your intro pathBy year:2025 · 42024 · 15 dated
South San Francisco, US
Mark Stepka(Executive Officer)Isabella Graef(Executive Officer, Director)Nathanael Gray(Director)
BoardWendy Young(Director)Jim Edwards(Director)
Board seatGary Yeung· per SEC Form D · $21.5M raise · filed May 2025
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesThe Column GroupDroia Ventures
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+3 more
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevity
William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in
BoardDaniel Gil(PhD)
Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILVisionary Ventures
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)in
Co-investorsNovartis Venture FundY CombinatorForbionGlilot Capital PartnersOmega Funds
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more
Vivere is a product development partner that helps brands, influencers, and companies ideate, create, manufacture, and distribute consumer product lines across categories including beauty, wellness and health, baby, pet care, and home and garden.
ConsumerDirect to ConsumerE-commerceWellness & FitnessHamburg, DE
Co-investorsArmada Investment AGFf Venture CapitalRockaway VenturesBerkeley FrontierPillarredalpine
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesPelage · hairlosscure2020.com · Jul 26, 2026
Pelage Pharmaceuticals · hairlosscure2020.com · Jul 26, 2026
Protego Biopharma · finsmes.com · Apr 23, 2026
Vivere · finsmes.com · Jan 14, 2026
Protego · globalgenes.org · Dec 1, 2025
Shenandoah Therapeutics Inc. · leadsontrees.com · Sep 2, 2025
Frequently asked questions
- How many investments has YK Bioventures made?
- YK Bioventures has 10 tracked investments, including 4 dated in the last 24 months.
- Where is YK Bioventures located?
- YK Bioventures is headquartered in Burlingame, US.